
The AI-powered cvi42 | Plaque software enables adjunctive on-site interpretation of coronary CT angiography (CCTA) scans for plaque quantification.

The AI-powered cvi42 | Plaque software enables adjunctive on-site interpretation of coronary CT angiography (CCTA) scans for plaque quantification.

Catch up on the most-well viewed radiology content in October 2025.

The newly launched PlaqueIQ™ image analysis modality is reportedly the first CT-based software indicated for the quantification and classification of plaque morphology in the carotid arteries.

For patients with esophageal cancer, preoperative MRI demonstrated an average AUC above 94 percent for detecting tracheal invasion in contrast to an AUC range between 52.9 and 70.6 percent for CT, according to a recently published study.

The Paradise Ultrasound Renal Denervation System has demonstrated efficacy and a favorable safety profile in randomized controlled trials for the treatment of mild, moderate and resistant hypertension.

In a retrospective analysis of triennial screening mammograms for 134,217 women, a deep learning model offered comparable assessment of interval breast cancer risk across differences in age and breast density.

The AI-enabled e-Lung software may lead to significantly improved and earlier detection of progressive pulmonary fibrosis, even in patients deemed clinically stable, according to new research recently presented at the American College of Chest Physicians (CHEST) conference.

While teleradiologists with flexible schedules may be the target of jealousy and vitriol on social media, the opportunities for improved work-life balance and increased flexibility are welcomed by others.

Offering real-time, high-resolution ultrasound imaging for a range of procedures, the zero-capex Intracardiac Imaging System reportedly facilitates workflow efficiencies and reduced costs.

New research on photon-counting computed tomography in 2025 reveals increasing capabilities of the technology to enhance CT visualization and characterization with significant reductions in radiation dosing in cardiovascular imaging, abdominal imaging and other diagnostic applications.

Designed for use in saline contrast echocardiography, the ASI-02 modality is currently being evaluated in a multicenter, randomized trial for patients undergoing transthoracic echocardiography (TTE).

In a review of nearly 1,300 emergency referrals for computed tomography (CT) scans, approximately 28 percent were deemed to have adequate requisition quality according to a RI-RADS analysis.

Noting an increased incidence of false negatives in screening and diagnostic mammography, researchers found that a personal history of breast cancer was associated with over a 3.6-fold higher likelihood of false negatives.

Use of the radiotherapeutic agent 177Lu-edotreotide (ITM-11) demonstrated significantly higher absorption in gastroenteropancreatic neuroendocrine tumors than normal organs along with a favorable safety profile, according to SPECT research recently presented at the European Association of Nuclear Medicine (EANM) conference.

Facilitating timely triage, the qER-CTA software enables AI assessment of the internal carotid artery and M1 segment of the middle cerebral artery for possible large vessel occlusions (LVOs).

Pre-op breast MRI was associated with a 12.5 percent reduced 5-year cumulative incidence of recurrence for patients who underwent surgery for hormone receptor-negative cancer, according to newly published research.

In a recent interview, Deepa Sheth, M.D., discussed the rising incidence of breast cancer, key considerations in supplemental imaging for women with dense breasts and use of the CIVIE RadPod platform to facilitate consistent quality and imaging reads by fellowship-trained breast radiologists.

Deep learning assessment of MRI offered a 24 percent higher sensitivity than radiologist interpretation for detecting lymph node metastasis in patients with colorectal cancer, according to a new meta-analysis.

Through the use of a multimodal system, Viz Assist provides generative AI summaries of patient histories that may ehance care coordination and facilitate more timely interventions.

Pluvicto in combination with the standard of care led to a 28 percent reduction in the risk of radiographic progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results from the phase III PSMAddition trial presented at the European Society for Medical Oncology (ESMO) conference.

Seemingly over the top efforts for recredentialing of radiologists may have an adverse impact on a facility’s retention and recruitment.

Catch up on the top radiology content of the past week.

The iron-based brain MRI contrast agent Ferabright (ferumoxytol injection) is indicated for adult patients with known or suspected malignant neoplasms.

Concordant mammography detection of breast cancer by radiologists and AI had over a threefold higher likelihood of future incidental breast cancer in comparison to positive radiologist assessment and negative AI evaluation, according to new research involving over 82,000 women.

The AI-enabled LungQ® 4 software reportedly offers enhanced segmentation of peripheral airways and estimates of chronic perfusion deficits based on analysis of chest CT scans.

Facilitating timely detection and follow-up management of patients with aortic aneurysms, the PRAEVAorta2 software reportedly enables automated measurement of aortic diameters on computed tomography (CT) scans.

While a new meta-analysis of the PI-RADS v2.1 criteria showed 96 percent and 88 percent sensitivity rates for PI-RADS category > 3 and PI-RADS category > 4 assessments respectively, researchers noted a high risk of bias in 29 percent of the reviewed studies.

New enhancements for the Venue POCUS devices include automated labeling of anatomical landmarks with Nerveblox to facilitate 12 common peripheral nerve blocks and contrast-enhanced ultrasound geared to abdominal injury assessments.

In the second part of a recent interview, Emmanuel S. Antonarakis, M.D. discusses PSMA PET agents in current trials and cell surface proteins that may offer targeting utility in prostate cancer imaging beyond PSMA.